Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 4, 2020
Myovant Sciences Ltd.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
(Commission File No.)
(I.R.S. Employer Identification No.)

Suite 1, 3rd Floor
11-12 St. James’s Square
London SW1Y 4LB
United Kingdom
Not Applicable
(Address of principal executive office)
(Zip Code)
Registrant’s telephone number, including area code:  +44 207 400 3351
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Shares, par value $0.000017727 per share
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 4, 2020, Kim Sablich, Chief Commercial Officer of Myovant Sciences, Inc., advised Myovant Sciences Ltd. that she was resigning from her position to take on a senior executive role at a multinational pharmaceutical company. Ms. Sablich’s last day of employment is expected to be May 22, 2020.
Item 8.01
Other Events.
Effective May 11, 2020, Adele Gulfo, Chief Business and Commercial Development Officer of Sumitovant Biopharma Inc. and board member of Myovant Sciences Ltd., will assume the role of interim Chief Commercial Officer, assuming commercial leadership responsibilities. Prior to joining Sumitovant, Ms. Gulfo served as Chief of Commercial Development at Roivant Sciences. She also served as Chief Strategy Officer, Executive Vice President, and Head of Global Commercial Development at Mylan, in addition to multiple executive leadership roles at Pfizer, including as President and General Manager of the U.S. primary care business unit. She has extensive experience in building commercial organizations and has led the launches of multiple new products, including LIPITOR®.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Myovant Sciences Ltd.
Date: May 8, 2020
/s/ Matthew Lang
Matthew Lang
General Counsel and Corporate Secretary